Breast Cancer Clinical Trials in Nanjing, Jiangsu
16 recruitingNanjing, Jiangsu, China
Showing 1–16 of 16 trials
Recruiting
Phase 1
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
Breast CancerAdvanced Solid Tumor
BeOne Medicines86 enrolled10 locationsNCT07222267
Recruiting
Phase 3
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Breast Cancer
Pfizer1,020 enrolled518 locationsNCT06760637
Recruiting
Phase 1Phase 2
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
Breast CancerAdvanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.414 enrolled20 locationsNCT07169994
Recruiting
Phase 3
Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer
Breast Cancer
Laekna Limited256 enrolled55 locationsNCT04851613
Recruiting
Phase 2
Prospective Study on Exemption of Tumor Bed Boost Radiotherapy for pCR Patients After Breast Conserving Surgery With Neoadjuvant Therapy
Breast Cancer
The First Affiliated Hospital with Nanjing Medical University150 enrolled1 locationNCT07113613
Recruiting
Phase 3
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.642 enrolled25 locationsNCT07003074
Recruiting
Not Applicable
Hypofractionated Radiation Fractionation in Breast Cancer Patients with Implant-Based Reconstruction
Breast Cancer
The First Affiliated Hospital with Nanjing Medical University840 enrolled1 locationNCT06830083
Recruiting
Not Applicable
A Clinical Study of Albumin-bound Paclitaxel/Granulocyte-based Therapy for Recurrent/Metastatic Breast Cancer
Breast Cancer
JIANG LONGWEI1 enrolled2 locationsNCT06496724
Recruiting
Not Applicable
To Evaluate the Effectiveness and Safety of Mastectomy Combined With Immediate Breast Reconstruction in Breast Cancer
Breast Cancer
The First Affiliated Hospital with Nanjing Medical University800 enrolled1 locationNCT06817954
Recruiting
Phase 1
The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study
Breast Cancer
The First Affiliated Hospital with Nanjing Medical University200 enrolled1 locationNCT06770296
Recruiting
Not Applicable
Omission of SLNB in CN0 Early Breast Cancer
Breast CancerSentinel Lymph NodeClinically Assessed Negative Axillary Lymph Nodes
The First Affiliated Hospital with Nanjing Medical University311 enrolled1 locationNCT05935150
Recruiting
Clinical Application of ctDNA Dynamic Monitoring in Neoadjuvant Therapy for HER2-positive Breast Cancer Patients
Breast CancerHER2-positive Breast CancerNeoadjuvant+1 more
The First Affiliated Hospital with Nanjing Medical University50 enrolled1 locationNCT06479460
Recruiting
Phase 2
Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer
Breast Cancer
The First Affiliated Hospital with Nanjing Medical University65 enrolled1 locationNCT05659056
Recruiting
Phase 2
The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study
Breast Cancer
The First Affiliated Hospital with Nanjing Medical University102 enrolled1 locationNCT06254690
Recruiting
Phase 2
A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer
Breast Cancer
The First Affiliated Hospital with Nanjing Medical University70 enrolled1 locationNCT06001086
Recruiting
Phase 3
A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
Breast Cancer
Genor Biopharma Co., Ltd.350 enrolled52 locationsNCT05851014